Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04885998 · ClinicalTrials.gov registry record · Phase 1
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT04885998 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 23 participants.
The verdict
NCT04885998, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Interventions
- DRUG Tarlatamab
- DRUG AMG 404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2024-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04885998
The ClinicalTrials.gov registry entry for NCT04885998 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tarlatamab is the first listed.
NCT04885998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04885998 about?
NCT04885998 is a clinical study titled "AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)". The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
What is the current status of trial NCT04885998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2021-09-27. Estimated completion is 2024-09-11.
What interventions are being tested in trial NCT04885998?
The interventions under investigation include: Tarlatamab (DRUG), AMG 404 (DRUG).
Who is sponsoring clinical trial NCT04885998?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.